Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 01, 2008. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights.
| Metric | Value |
|---|---|
| Issued Share Capital (as of April 30, 2008) | 5,866,590,834 Ordinary shares of 25p each |
| Treasury Shares | 484,194,158 Ordinary shares |
| Total Voting Rights | 5,382,396,676 |
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period regarding financial performance or operational metrics. The document only states the current capital structure as of April 30, 2008.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The primary purpose of this filing is to inform shareholders of the denominator to be used for calculating notification thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of voting rights (5,382,396,676) for compliance with disclosure thresholds.
- Confirm the number of shares held in Treasury (484,194,158) to understand the float.
- Note that this filing contains no financial performance data; refer to Form 20-F for financial statements.